Zotarolimus

Star0

DB18761InvestigationalSmall molecule

Zotarolimus is an immunosuppressant under investigation for use in drug-eluting stents.

Mechanism: Pharmacologically active on Peptidyl-prolyl cis-trans isomerase FKBP1A
Curator reviewed
Formula / weight: C₅₂H₇₉N₅O₁₂ · 966.227 g/mol (avg)
Code names: ABT-578 · MDT-4107

Resolves to

Compound

UNIIH4GXR80IZECAS221877-54-9ChEMBLCHEMBL219410ChEBI135897

Structure

InChIKeyCGTADGCBEXYWNE-JUKNQOCSSA-NSMILES

[H][C@@]12CC[C@@H](C)[C@@](O)(O1)C(=O)C(=O)N1CCCC[C@@]1([H])C(=O)O[C@@]([H])(CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C2)OC)[C@H](C)C[C@@H]1CC[C@@H]([C@@H](C1)OC)N1C=NN=N1

Targets

P62942FKBP1AP42345MTOR

What you can answer from here — as of November 02, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zotarolimus, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account